Bacteriophage therapy of Salmonella enterica: a fresh appraisal of bacteriophage therapy

Rosanna Capparelli,Nunzia Nocerino,Marco Iannaccone,Danilo Ercolini,Marianna Parlato,Medaglia Chiara,Domenico Iannelli
DOI: https://doi.org/10.1086/648478
2010-01-01
Abstract:Background: The most serious criticisms leveled at bacteriophage therapy are as follows: phages induce neutralizing antibodies, phages are active only when administered shortly after bacterial infection, and phage-resistant bacteria emerge rapidly in the course of therapy. Methods: Phages lytic for several Salmonella enterica serovars were isolated by means of standard protocols from feces of patients with gastroenteritis. Growth of S. enterica serovar Paratyphi B (Salp572(phi1S)) in the presence of phage phi1 (selected from among 8 phages for its larger host range) provided a phage phi1-resistant bacterial strain (Salp572(phi1R)). The properties of the Salp572(phi1S) and Salp572(phi1R) strains and of phage phi1 were studied in a mouse model of experimental infection. Results: Phages induced nonneutralizing antibodies and were active 2 weeks after experimental infection of mice; phage-resistant bacteria were avirulent and short lived in vivo. More importantly, phage-resistant bacteria were excellent vaccines, protecting against lethal doses of heterologous S. enterica serovars. Conclusions: Phage therapy effectiveness has not yet been properly assessed.
What problem does this paper attempt to address?